Female stress incontinence

Summary

Female stress incontinence (MONDO:0004160) is a disease and 10 clinical trials. A subtype of urinary bladder disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	female stress incontinence
Mondo ID	MONDO:0004160
DOID	DOID:724
NCIT	C35042
UMLS	C0038437
MedGen	21346
Is cancer (heuristic)	no

Disease family

This is a subtype of urinary bladder disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › female stress incontinence

Related subtypes (16): low compliance bladder, detrusor sphincter dyssynergia, urinary bladder tuberculosis, urinary bladder neoplasm, urinary schistosomiasis, vesicoureteral reflux, cystitis, overactive bladder, bladder calculus, bladder neck obstruction, postcholecystectomy syndrome, ureterolithiasis, bladder diverticulum, ureterocele, Hinman syndrome, disorder of neck of urinary bladder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05207189	PHASE2	COMPLETED	Biological Sling Allograft (UVT) for the Treatment of Urinary Incontinence in Women Presenting With Synthetic Sling Complications
NCT01230450	PHASE1	COMPLETED	Feasibility of Comparing Two Surgical Treatment of Female Urodynamic Stress
NCT06451796	Not specified	RECRUITING	Investigation of Novel Non-CE Marked Catheter
NCT01673360	Not specified	TERMINATED	Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices
NCT03106103	Not specified	COMPLETED	Incidence of Symptomatic and Asymptomatic Bacteriuria After Urodynamic Study in Women
NCT03174431	Not specified	COMPLETED	Continence Pessary Versus Disposable Intravaginal Device Trial
NCT03682926	Not specified	COMPLETED	Electrostimulation PROTOCOL Incontinence
NCT03727945	Not specified	COMPLETED	Posture in Abdominopelvic Training in Women SUI
NCT03996070	Not specified	COMPLETED	VESPER: Stress Urinary Incontinence STUDY
NCT05448482	Not specified	UNKNOWN	Hybrid Versus Synthetic TOT for Treatment of SUI